Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Effects of the Timing of Venous Thromboembolic Events on Survival of Patients with Uterine Cancer

Heera Remasankar, MD, Xiao Zhou, MD PhD, Saroj Vadhan-Raj, MD

Blood (2014) 124 (21): 1534.

https://doi.org/10.1182/blood.V124.21.1534.1534

Published: 2014

Journal Articles

Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE

Saroj Vadhan-Raj, MD, Xiao Zhou, MD, PhD, Gauri R. Varadhachary, MD, MBBS, Javle Milind, MD, David Fogelman, MD, Rachna Shroff, MD, Carlos E. Bueso-Ramos, MD, PhD, Martin Nguyen, BS, Xuemei Wang, MS, Robert A. Wolff, MD, James L. Abbruzzese, MD, Michael J. Overman, MD

Blood (2013) 122 (21): 580.

https://doi.org/10.1182/blood.V122.21.580.580

Published: 2013

Journal Articles

Effects of Multiple Myeloma (MM) Therapy and Type of Thromboprophylaxis On the Incidence and Timing of Venous Thromboembolism (VTE) and Factors Predictive of VTE.

Jatin J. Shah, M.D., Aparna Hegde, MD, Xiao Zhou, MD, PHD, Sheeba K. Thomas, MD, Michael Wang, MD, Donna M. Weber, M.D., Raymond Alexanian, MD, Robert Z. Orlowski, MD, PhD, Saroj Vadhan-Raj, MD

Blood (2012) 120 (21): 2244.

https://doi.org/10.1182/blood.V120.21.2244.2244

Published: 2012

Journal Articles

Interleukin-6, Hepcidin, and Other Biomarkers in Anemia of Chronic Disease (ACD) and Chemotherapy-Induced Anemia (CIA): Potential Therapeutic Targets.

Saroj Vadhan-Raj, MD, Xiao Zhou, MD, PHD, Carlos E. Bueso-Ramos, MD, PhD, Shreyaskumar Patel, MD, Robert S Benjamin, MD, Martin Ngyuen

Blood (2012) 120 (21): 2086.

https://doi.org/10.1182/blood.V120.21.2086.2086

Published: 2012

Journal Articles

Effects of the Timing and the Type of Venous Thromboembolic Events On Survival in Patients with Pancreatic Cancer

Vivek Kesari, MD, Maithili Shethia, MD, Xiao Zhou, MD, PHD, Michael Overman, MD, Saroj Vadhan-Raj, MD

Blood (2012) 120 (21): 1151.

https://doi.org/10.1182/blood.V120.21.1151.1151

Published: 2012

Journal Articles

Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

Saroj Vadhan-Raj, MD, Ivan Spasojevic, Ph.D., Xiao Zhou, MD, PHD, Jorge E Romaguera, MD, Michelle A. Fanale, MD, Luis E Fayad, MD, Nathan H. Fowler, MD, Auris Huen, PHARMD, F.B. Hagemeister, MD, Maria Alma Rodriguez, MD, Sattva S. Neelapu, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry W Kwak, MD, PhD

Blood (2011) 118 (21): 1613.

https://doi.org/10.1182/blood.V118.21.1613.1613

Published: 2011

Journal Articles

Venous Thromboembolism (VTE) in Patients with Hematologic and Non-Hematologic Malignancies: Incidence and Risk Factors for Recurrent VTE

Saroj Vadhan-Raj, MD, Xiao Zhou, MD, PHD, Jatin J Shah, MD, Robert S Benjamin, MD, Gregory Gladish, MD

Blood (2011) 118 (21): 2303.

https://doi.org/10.1182/blood.V118.21.2303.2303

Published: 2011

Journal Articles

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Saroj Vadhan-Raj, MD, Fredrick Hagemeister, Luis E. Fayad, MD, Xiao Zhou, MD, PHD, Shana Sherril ORoark, APN, Kandice Ames, RN, Maria Alma Rodriguez, MD, Michelle A. Fanale, MD, Barbara Pro, MD, Marcella M. Johnson, MS, Peter McLaughlin, MD, Carlos E. Bueso-Ramos, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Enrique Romaguera

Blood (2010) 116 (21): 1544.

https://doi.org/10.1182/blood.V116.21.1544.1544

Published: 2010

Journal Articles

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

Saroj Vadhan-Raj, MD, Luis Fayad, MD, Michelle Fanale, M.D., Barbara Pro, Alma Rodriguez, Frederick Hagemeister, Kandice Ames, RN, Carlos E. Bueso-Ramos, MD, Xiao Zhou, MD, PHD, Peter McLaughlin, Nathan Fowler, Jatin Shah, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 105.

https://doi.org/10.1182/blood.V114.22.105.105

Published: 2009

Journal Articles

Impact of Safety Concerns of Erythropoiesis-Stimulating Agents (ESAs) and Regulatory Changes on the Use of ESAs and Red Blood Cell (RBC) Transfusions at a Comprehensive Cancer Center

Saroj Vadhan-Raj, UTMD, Victoria E. Hawkins, MPH, DRPH, RN, Xiao Zhou, MD, PHD, Kurt Sizer, MD, Lincy S. Lal, PHD, PHARMD, RPH, Joyce Roquemore, MBA, CPHQ, Rebecca B. Arbuckle, MS, RPH, Robert S. Benjamin, MD, BA, Benjamin Lichtiger, MD, PhD

Blood (2008) 112 (11): 1300.

https://doi.org/10.1182/blood.V112.11.1300.1300

Published: 2008

Journal Articles

High Incidence of Venous Thromboembolism in Patients with Lymphoma Receiving Chemotherapy: Assessment of Risk Factors.

Shyam Teegala, MD, Xiao Zhou, MD, PhD, Auris Huen, PHARMD, Yuan Ji, PhD, Luis Fayad, M.D., Jorge Enrique Romaguera, M.D., F.B. Hagemeister, M.D., Saroj Vadhan-Raj, M.D.

Blood (2006) 108 (11): 4103.

https://doi.org/10.1182/blood.V108.11.4103.4103

Published: 2006

Journal Articles

Incidence and Risk Factors for Severe Thrombocytopenia in Lymphoma Patients Receiving Chemotherapy.

Auris Huen, PharmD, Xiao Zhou, MD, PhD, Shyam Teegala, M.D., Yuan Ji, PhD, Luis Fayad, M.D., Jorge Enrique Romaguera, M.D., F.B. Hagemeister, M.D., Saroj Vadhan-Raj, M.D.

Blood (2006) 108 (11): 3994.

https://doi.org/10.1182/blood.V108.11.3994.3994

Published: 2006

NARROW

Effects of the Timing of Venous Thromboembolic Events on Survival of Patients with Uterine Cancer

Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE

Effects of Multiple Myeloma (MM) Therapy and Type of Thromboprophylaxis On the Incidence and Timing of Venous Thromboembolism (VTE) and Factors Predictive of VTE.

Interleukin-6, Hepcidin, and Other Biomarkers in Anemia of Chronic Disease (ACD) and Chemotherapy-Induced Anemia (CIA): Potential Therapeutic Targets.

Effects of the Timing and the Type of Venous Thromboembolic Events On Survival in Patients with Pancreatic Cancer

Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

Venous Thromboembolism (VTE) in Patients with Hematologic and Non-Hematologic Malignancies: Incidence and Risk Factors for Recurrent VTE

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

Impact of Safety Concerns of Erythropoiesis-Stimulating Agents (ESAs) and Regulatory Changes on the Use of ESAs and Red Blood Cell (RBC) Transfusions at a Comprehensive Cancer Center

High Incidence of Venous Thromboembolism in Patients with Lymphoma Receiving Chemotherapy: Assessment of Risk Factors.

Incidence and Risk Factors for Severe Thrombocytopenia in Lymphoma Patients Receiving Chemotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only